Clinical Trials and Research
Cardiac amyloidosis, traditionally considered a rare and dire disease, is receiving increasing attention as sophisticated diagnostics are identifying more patients…
Although most patients with familial amyloid polyneuropathy (FAP) who undergo liver transplant will require a pacemaker, implanting the device before the transplant…
AL amyloidosis is a rare condition caused when bone marrow produces abnormal antibodies that can't be broken down and are deposited in tissues, interfering with…
Once used to diagnose myocardial infarction, technetium-99m pyrophosphate (Tc 99m PYP) imaging may be reborn as an alternative to biopsy for diagnosing cardiac…
The FDA announced that it has approved patisiran infusion for the treatment of patients with peripheral nerve disease caused by hereditary transthyretin-mediated…
A UCL-led study has confirmed that some vials of a hormone used in discontinued medical treatments contained seeds of a protein implicated in Alzheimer's disease,…
Tiny protein structures called amyloids are key to understanding certain devastating age-related diseases. Aggregates, or sticky clumped-up amyloids, form plaques…
Toxic protein assemblies, or "amyloids," long considered being key drivers in many neuromuscular diseases, also playing a beneficial role in the development of…
Pfizer Inc. announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the…
Eidos Therapeutics, Inc., today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with Transthyretin (TTR)…